• Batimastat (BB-94) Workflows for MMP Studies

  2026-08-28

  Batimastat (BB-94) combines nanomolar, broad-spectrum MMP inhibition with a practical DMSO-based workflow for cancer, extracellular-matrix, and developmental neuroscience studies. This guide shows how to connect enzyme assays, tumor models, and localized BDNF processing while distinguishing established product evidence from exploratory neuromuscular-junction applications.

• Rhodamine B for Mechanism-Driven Bioassays

  2026-08-28

  Rhodamine B is more than a bright label: it can provide a practical optical readout for cell localization, assay quality, and trigger-responsive biology. This guide connects Basic Violet 10 with mechanistic assay design while clarifying what fluorescence can—and cannot—prove.

• ATF4 Enhancer Program in Liver Fibrosis

  2026-08-27

  The reference study identifies a non-canonical, stress-response-independent role for ATF4 in hepatic stellate cells, where TGFβ redirects ATF4 toward an enhancer program that activates pro-fibrotic EMT genes. Genetic depletion of ATF4 and pharmacological suppression of its translation reduced fibrosis in experimental models, supporting ATF4-regulated chromatin control as a potential therapeutic entry point.

• Telatinib (BAY 57-9352) Assay Workflow

  2026-08-27

  Build mechanism-aware angiogenesis, invasion, and signaling assays with Telatinib, a multi-kinase inhibitor spanning VEGFR, c-Kit, and PDGFR pathways. This workflow translates TNBC findings into practical dose handling, phenotype selection, combination testing, and troubleshooting strategies.

• HNRNPU K181 Lactylation Reprograms Serine Metabolism

  2026-08-26

  This Advanced Science study identifies HNRNPU lysine 181 lactylation as a molecular link between lactate accumulation, PHGDH expression, serine biosynthesis, and cervical cancer growth. Its results define a competitive lactylation–acetylation switch and suggest that site-specific post-translational regulation may be a tractable target for metabolic intervention, although pharmacological specificity and broader clinical transferability require further validation.

• Br-DAPI: DAPI Fluorescent Dye for DNA Imaging

  2026-08-26

  Br-DAPI is a DAPI fluorescent dye and DNA quantification dye that binds A/T-rich regions in double-stranded DNA and increases fluorescence after binding. Its membrane permeability supports live cell DNA staining and fixed cell DNA staining, while careful controls are required to distinguish DNA signal from apoptosis or ER-stress biology.

• HNRNPU K181 Lactylation in Cervical Cancer

  2026-08-26

  This Advanced Science study identifies HNRNPU lysine 181 lactylation as a non-histone regulatory mechanism that connects lactate accumulation with PHGDH-dependent serine biosynthesis in cervical cancer. The findings link a post-translational modification switch to RNA stability, redox balance, nucleotide production, tumor growth, and a pharmacological response to Pazopanib.

• TMEM16F Scrambling Links Ferroptosis to Tumor Immunity

  2026-08-25

  Yang et al. identify TMEM16F-mediated plasma-membrane phospholipid scrambling as a late-stage suppressor of ferroptotic membrane failure. The study further shows that disabling this repair-like response promotes lytic death, danger-signal release, slower tumor growth, and stronger responses to PD-1 blockade in preclinical models.

• Hesperadin: Aurora B Kinase Workflow Guide

  2026-08-24

  Hesperadin is an ATP-competitive Aurora B kinase inhibitor for dissecting histone H3 phosphorylation, chromosome segregation, cytokinesis, and polyploidization. This practical guide combines cell-based workflows with checkpoint-complex controls so researchers can distinguish Aurora-driven phenotypes from direct effects on MCC disassembly.

• Fluoxetine HCl: Mechanism and Research Workflows

  2026-08-24

  Fluoxetine HCl is a selective serotonin reuptake inhibitor used to interrogate serotonin transport, 5-HT2C signaling, neurogenesis, and reward-related behavior. Its acute molecular effects should be separated from developmental SSRI exposure, which is associated with persistent motivational phenotypes in preclinical models.

• REV1–DHX36 Control of G-Quadruplex Replication

  2026-08-23

  A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The findings establish a two-tier mechanism for G4 tolerance and connect REV1 deficiency with increased ATM/ATR signaling and sensitivity to G4-stabilizing agents.

• PR-619 for DUB Inhibition Workflows

  2026-08-22

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for separating DUB-dependent ubiquitin accumulation from direct proteasome blockade. This guide translates its chemistry into practical workflows for ubiquitination pathway research, autophagy assays, cancer biology, and carefully bounded immuno-oncology experiments.

• CMA Decline, SERCA Dysfunction, and Age-Related Myopathy

  2026-08-21

  This Nature Metabolism study establishes chaperone-mediated autophagy (CMA) as an active regulator of skeletal muscle maintenance rather than a passive lysosomal pathway. Using reporter, genetic, proteomic, physiological, and human-tissue analyses, the authors connect age-related CMA loss to impaired SERCA turnover, calcium dysregulation, muscle weakness, and progressive myopathy.

• MG-132 (Z-LLL-al) in LUAD Proteasome Workflows

  2026-08-20

  MG-132 (Z-LLL-al) provides an acute, cell-permeable way to test whether proteasome-dependent protein turnover contributes to LUAD phenotypes. This workflow-focused guide connects PSMA4–p53 biology with apoptosis assays, cell cycle arrest studies, ROS measurements, and practical troubleshooting.

• RQ3025: Broad-Spectrum mRNA Vaccine Preclinical Study

  2026-08-20

  This 2024 preclinical study evaluates RQ3025, a bivalent mRNA vaccine designed around conserved and variant-associated SARS-CoV-2 spike mutations. Across mice, hamsters, and rats, the vaccine generated broad neutralizing activity, protected rats from several variants, induced a Th1-biased response, and showed no apparent organ pathology in a high-dose safety assessment.

8408 records 1/561 page Next 12345 下5页 Last page